Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis announced its share and voting rights update as of July 31, 2022. The total number of ordinary shares in circulation stands at 45,510,810, with total voting rights reaching 51,875,672. This report is part of compliance with the French financial markets authority regulations.

As a leading clinical-stage biotechnology company, Cellectis is focused on developing innovative cell and gene therapies utilizing its gene-editing technology, TALEN®, and aims to address unmet medical needs in oncology.

Positive

• Cellectis holds a total of 45,510,810 shares, indicating stable share capital.
• The increase in voting rights to 51,875,672 shows a solid shareholder engagement.

Negative

• None.

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, Aug. 22, 2022 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
07/31/2022	45,510,810	51,875,672

About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomal storage diseases.

Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina.

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit www.cellectis.com
Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

For further information, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com
Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300

Investor Relation contact:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 (617) 430 7577

Attachment

• Voting_Rights_PR_July_EN_docx

FAQ

What is the latest update on Cellectis shares?

As of July 31, 2022, Cellectis reported a total of 45,510,810 shares.

What are the total voting rights for Cellectis as of July 2022?

Cellectis has a total of 51,875,672 voting rights as of July 31, 2022.

What is Cellectis' focus in biotechnology?

Cellectis is focused on developing innovative cell and gene therapies using gene-editing technology for various cancers.

On which market is Cellectis listed?

Cellectis is listed on both the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS).